More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

Biopharmaceutical companies invest approximately $75 billion annually in R&D in the US, more than any other industry in the US. There are more than 7,000 drugs in development, with more than three-quarters defined as first-in-class, meaning...

A recent study by PwC examines the thinking and strategic direction of CEOs and how their views compare with the perceptions and expectations of investment professionals. So what did the study show? Investment professionals and CEOs both think...

Vasant Narasimhan, MD, took the helm of Novartis on February 1, 2018, assuming the role of CEO following the retirement of former CEO Joseph Jimenez. So what does the new CEO face? Key for Narasimhan will be to drive growth in the company's...

In its annual assessment of technology advances, Accenture highlights that rapid advancements in technologies, including artificial intelligence, advanced analytics and the cloud, are enabling companies to not just create innovative products and...

What do parenteral drugs and healthcare reform have in common? Recent reports point to the relationship between the high cost of specialty drugs, often parenteral drugs administered in hospitals. So what did the reports show and what are the...

Small molecules remain the dominant modality in pharmaceuticals based on approvals of new molecular entities (NMEs), but biologics continue to make inroads. So what do the numbers show? Small molecules accounted for nearly three-fourths of NME...

A recent study from Accenture and HFS Research points to the need to have “intelligent operations” to drive business outcomes. So what is a winning approach for “intelligent operations?” The study surveyed nearly 500 executives to analyze the...